AKESO (09926) saw an early trading surge of over 3%, reaching a 2.83% increase to HK$120.2 by the time of reporting, with a trading volume of HK$100 million. On December 11, AKESO announced via its official WeChat account that updated efficacy data from a Phase II clinical study of its independently developed PD-1/VEGF bispecific antibody, Ivonescimab, combined with chemotherapy for first-line treatment of locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), were presented at the 2025 European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) in London. The data demonstrated the significant clinical potential of Ivonescimab in first-line TNBC treatment.
Previously, due to its outstanding efficacy and safety, Ivonescimab's combination therapy for first-line TNBC treatment was included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation (CDE). Currently, a multicenter, randomized, double-blind Phase III clinical trial (HARMONi-BC1/AK112-308) for this indication is progressing efficiently.
Ivonescimab, developed by AKESO, is the world's first PD-1/VEGF bispecific antibody for tumor immunotherapy. Its first indication was approved by China's National Medical Products Administration (NMPA) in May 2024 for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) following EGFR-TKI therapy progression. Ivonescimab became the first globally approved bispecific antibody drug with a synergistic "tumor immunotherapy + anti-angiogenesis" mechanism. In November of the same year, it was included in China's National Reimbursement Drug List.
Comments